reason report
cut bait vibativ anoth jaki surfac pt
financi result provid updat investor
develop progress upcom mileston vibativ revenu
consensu estim long-
term revenu outlook compromis discontinu
phase trial bacteremia indic re-deploy
vibativ commerci support immin revefenancin launch
suffer setback phase trial revefenacin
copd patient lower peak inspiratori flow rate pifr
seem unlik impact on-going regulatori review base
exist phase trial develop timelin
mid- late-stag pipelin product re-affirmed
compani announc new inhal jak inhibitor
move clinic later year earli next year
collabor agreement janssen op strengthen
confid strategi local deliveri pan-jak inhibitor
mucoc surfac therav portfolio continu shift
compani commit velusetrag program
gastroparesi invest nep inhibitor seem
wane lower probabl success
program cut vibativ revenu forecast perpetu
result revenu earn forecast come
price target reduc reiter outperform
net debt total capit
dcf use dr tgr
compani inform leerink partner llc research
revenu million ep quarterli ep may total annual sum due chang share outstand
pleas refer page import disclosur price chart analyst certif
rate share outperform therav biotechnolog compani form via
spin-out thrx divers set asset robust engin
previous help support fda approv multipl drug includ anoro breo vibativ
rel biotechnolog specialti pharma peer believ benefit
expertis drug deliveri compani late earli stage pipelin product oper via
proven mechanisms-of-act seek attain differenti either beneficial/
use mode administr revefenacin better safeti /- wider therapeut window td-
one commerci product vibativ antibiot indic
complic skin skin structur infect csssi hospit acquir pneumonia caus
mrsa skin/pneumonia infect concurr staph bacteremia addit
indic studi recent expand sale forc believ vibativ could time
becom cash flow posit franchis us meanwhil partner
fund develop tbph revefenacin nebul formul long act
muscarin antagonist lama w/ posit phase data patient compani
anticip potenti us approv passiv recipi stand earn
net royalti sale gsk close tripl trelegi recent
approv us prior medacorp survey work suggest success close tripl
could becom stapl copd standard-of-car model deriv blockbust
oppt extent counterbal physician enthusiasm w/ learn slower-than-
expect launch breo/anoro arriv ww tripl sale peak beyond
tbph commercial/partn asset compani also develop improv jak inhibitor
jaki partner improv nep inhibitor nepi treatment ulcer
coliti heart failur drug leverag proven mechanisms-of-act via
target profil may safer and/or benefit wider therapeut window
revenu consensu estim
forecast total revenu declin y/i larg due gener competit vibativ
total expens quarter non-cash stock compens
consensu estim forecast expens quarter
came consensu estim expens line
sequenti sg expens consensu estim
forecast expens line sequenti report loss
oper came consensu estim
forecast higher net loss primarili driven increas
employee-rel cost share-bas compens sg expens ep
basi report ep consensu estim
expect despit higher oper expens
maintain strong cash posit end cash plu
up-front payment receiv janssen earlier month provid suffici runway fund
compani well even without count royalti gsk trelegi ellipta
potenti profit share revefenacin approv compani provid guidanc
oper loss full-year exclud share-bas compens
includ partial revenu recognit up-front payment janssen
shift focu away vibativ revefenacin announc discontinu
phase trial vibativ bacteremia appar due slow accrual lack statist power
trial determin interim data safeti monitor committe compani conclud
increment invest requir reach requir power trial justifi
potenti commerci return reason studi halt note
cours alreadi reduc commerci spend vibativ given
headwind face in-hospit antibiot market light potenti regulatori approv
revefenacin direct promot effort acut care organ
failur revefenacin add-on trial critic pend nda forecast
anoth disappoint came efficaci result phase trial revefenacin
copd patient sub-optimal peak inspiratori flow rate pifr comparison tiotropium
revefenacin demonstr nomin statist signific improv lung function
subgroup patient sever sever diseas benefit fail achiev
statist signific overal popul compani reiter result
need exist nda revefenacin pdufa date novemb
year reason trial appear least confirm nebul provid
benefit patient sever diseas failur trial affect probabl
success revenu forecast revefenacin
janssen collabor track enter phase earlier month
enter collabor agreement janssen develop local pan-jak
inhibitor accord agreement initi phase studi ulcer
coliti uc phase studi crohn diseas cd although previous
delay enrol phase trial uc complet enrol remain
patient continu treatment schedul compani adher
previou plan initi pivot trial regardless progress phase studi
data remain two cohort report later upon agreement janssen time
manner disclosur hope disclosur come medic meet
orphan drug could mark transit continu observ emerg
signal potenti benefit singl ascend dose part exploratori phase
trial neurogen orthostat hypotens noh patient respond initi treatment
elig proceed second part repeat dose period month
although compani plan perform statist analysi due small size
exploratori natur trial believ studi could demonstr benefit
importantli durabl benefit could differenti current
avail treatment option result trial expect becom avail
knowledg on-going trial plan start phase trial indic later
year earli next year seek full approv studi compani
pursu busi model licens profit-shar three advanc product
vibativ trelegi ellipta revefenacin express desir retain full econom
compani transit matur stage
velusetrag develop still uncertain sinc complet phase studi
velusetrag gastroparesi last year engag activ discuss
regul us europ partner europ alfasigma regard design
phase studi compani releas updat phase plan well intent
collabor partner alfasigma
releas call also announc go move new inhal pan-jak
inhibitor inhibit activ clinic develop late earli initi
patient steroid-refractori asthma molecul differ structur physic
properti allow remain local lung inhal design
ration similar intent deliv steroid-lik anti-inflammatori activ
without advers event safeti liabil medicin furthermor pan-jak
inhibit activ could suppress asthma also
asthma give product advantag system administ competitor
model updat better estim time launch oper expens
outer year follow updat financi result quarter manag
disclosur made signific chang revenu expens earn forecast
therav specif cut vibativ revenu forecast slowli declin sale
rather slowli grow lower probabl success po velusetrag
previous po remain updat revenu forecast
consensu due account up-front payment janssen
fall recent consensu outer year revenu expect
respiratori drug unchang overal revenu forecast reduc
reduc later year
increas total oper expens forecast base invest
develop compani clinic program increas sg expens
support immin launch revefenacin dilut ep loss increas
increas per share continu forecast break-even later
earli although posit ep estim significantli lower recent
consensu price target reduc reiter outperform rate
therav stock compani diversifi portfolio product continu engag
investor although increasingli uncertain program
partner asset advanc pivot trial approv commerci first
equival
chang
chg work cap
share outstand includ option warrant
loss oper
loss incom tax
provis incom tax
share count period basic dilut
guidanc
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
phase trial result
time
mid high dose
leerink partner research compani report present clinicaltri gov
